. 2020 Mar 26;25(12):1900427. doi: 10.2807/1560-7917.ES.2020.25.12.1900427

Table 3. Sensitivity and specificity of the ReaScan TBE IgM rapid test^a (n = 313 samples).

Type of patients	ReaScan^a result			Total	Sensitivity^b (95% CI)	Specificity^c (95% CI)
Type of patients	TBE positive	TBE equivocal	TBE negative	Total	Sensitivity^b (95% CI)	Specificity^c (95% CI)
TBE patients	171	1	0	172	99.4% (96.8–100%)	97.9% (93.9–99.6%)
Non-TBE patients	1	2	138	141	99.4% (96.8–100%)	97.9% (93.9–99.6%)

CI: confidence interval; TBE: tick-borne encephalitis.

^a ReaScan TBE IgM rapid test (Reagena, Toivala, Finland).

^b Equivocal results calculated as false negative.

^c Equivocal results calculated as false positive.

In this table, samples were not from patients known to have vaccinations, or infections other than with TBE virus, that might cause diagnostic problems such as serological cross-reactions.

Table 3. Sensitivity and specificity of the ReaScan TBE IgM rapid testa (n = 313 samples).

Table 3. Sensitivity and specificity of the ReaScan TBE IgM rapid test^a (n = 313 samples).